How have EVOK shares performed in 2024?

Evoke Pharma's stock was trading at $1.0503 at the beginning of the year. Since then, EVOK stock has decreased by 52.6% and is now trading at $0.4980. View the best growth stocks for 2024 here .

Are investors shorting Evoke Pharma?

Evoke Pharma saw a decline in short interest in March. As of March 31st, there was short interest totaling 53,400 shares, a decline of 25.9% from the March 15th total of 72,100 shares. Based on an average daily volume of 62,100 shares, the short-interest ratio is currently 0.9 days. Currently, 0.8% of the shares of the company are sold short. View Evoke Pharma's Short Interest .

When is Evoke Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our EVOK earnings forecast .

How were Evoke Pharma's earnings last quarter?

Evoke Pharma, Inc. (NASDAQ:EVOK) released its earnings results on Thursday, March, 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. The specialty pharmaceutical company earned $1.68 million during the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative trailing twelve-month return on equity of 517.99%.

When did Evoke Pharma's stock split?

Evoke Pharma's stock reverse split before market open on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What guidance has Evoke Pharma issued on next quarter's earnings?

Evoke Pharma issued an update on its FY 2024 earnings guidance on Thursday, March, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.0 million-$14.0 million, compared to the consensus revenue estimate of $14.0 million.

What other stocks do shareholders of Evoke Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH) , InterDigital (IDCC) , STAG Industrial (STAG) , Advanced Micro Devices (AMD) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) , Inovio Pharmaceuticals (INO) , Pfizer (PFE) , Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY) .

How do I buy shares of Evoke Pharma?

Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:EVOK

Evoke Pharma (EVOK) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free EVOK Stock Alerts

$0.47

-0.01 (-2.15%)

(As of 04:21 PM ET)

Compare

Today's Range: $0.47
▼
$0.50
50-Day Range: $0.47
▼
$0.75
52-Week Range: $0.42
▼
$2.42

Volume: 1,943 shs
Average Volume: 56,073 shs
Market Capitalization: $3.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Earnings Financials Headlines SEC Filings Short Interest Social Media

Get Evoke Pharma alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Evoke Pharma Stock (NASDAQ:EVOK)

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

EVOK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EVOK Stock News Headlines

April 18, 2024 | americanbankingnews.com

Evoke Pharma (NASDAQ:EVOK) Stock Crosses Below 200 Day Moving Average of $0.93

April 18, 2024 | americanbankingnews.com

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

April 19, 2024 | Behind the Markets (Ad)

Forget NVIDIA, buy this $2 AI stock now…

This company is at the center of a trillion-dollar industry, fighting for a piece of a massive $20 billion pentagon contract.

April 17, 2024 | finance.yahoo.com

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

April 17, 2024 | globenewswire.com

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications

April 10, 2024 | finanznachrichten.de

DelveInsight Business Research, LLP: Gastroparesis Market to Witness Upsurge in Growth at a CAGR of 7% by 2034 | DelveInsight

April 10, 2024 | msn.com

Empowering students: Innovative approaches to climate change education

April 10, 2024 | finance.yahoo.com

Stephanie Carman Joins Underscore Marketing as SVP Client Services; Tiffany Marg Joins Strategy Team

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 10, 2024 | americanbankingnews.com

Evoke Pharma (NASDAQ:EVOK) Stock Passes Below Two Hundred Day Moving Average of $0.96

April 10, 2024 | americanbankingnews.com

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com

April 1, 2024 | msn.com

How a Dubai man built a $200,000 art collection in his Business Bay home

March 30, 2024 | msn.com

The Secret Behind Your Soda: The Cocaine-Free Journey of Coca Leaves in Coca-Cola

March 30, 2024 | msn.com

Brain-Triggered Snacking: A New Understanding of Eating Impulses : ScienceAlert

March 22, 2024 | finanznachrichten.de

Evoke Pharma, Inc.: Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

March 21, 2024 | marketwatch.com

Evoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO Gonyer

March 21, 2024 | finance.yahoo.com

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer

March 21, 2024 | globenewswire.com

Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer

March 18, 2024 | msn.com

Big change is the only constant in eco: India Inc

March 17, 2024 | seekingalpha.com

Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript

March 16, 2024 | finance.yahoo.com

Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?

March 15, 2024 | msn.com

Brain gain: Hope rises with new dementia treatments

March 15, 2024 | finance.yahoo.com

Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript

March 15, 2024 | finanznachrichten.de

Evoke Pharma, Inc.: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

March 15, 2024 | msn.com

EVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023

March 14, 2024 | msn.com

‘Would have torn Modi into pieces’: DMK minister TM Anbarasan booked for remarks against PM

March 14, 2024 | globenewswire.com

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

See More Headlines

Receive EVOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/14/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EVOK
CUSIP: N/A
CIK: 1403708
Web: www.evokepharma.com
Phone: (858) 345-1494
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,790,000.00
Net Margins: -150.43%
Pretax Margin: -150.40%
Return on Equity: -517.99%
Return on Assets: -91.83%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.25
Quick Ratio: 2.09

Sales & Book Value

Annual Sales: $5.18 million
Price / Sales: 0.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.77) per share
Price / Book: -0.62

Miscellaneous

Outstanding Shares: 8,480,000
Free Float: 7,479,000
Market Cap: $4.06 million
Optionable: Not Optionable
Beta: 0.22

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. David A. Gonyer R.Ph. (Age 60)
Co-Founder, CEO & Director
Comp: $666.31k
Mr. Matthew J. D'Onofrio MBA (Age 54)
Co-Founder, President, COO, Secretary & Treasurer
Comp: $498.12k
Dr. Marilyn R. Carlson D.M.D. (Age 76)
M.D., RAC., Chief Medical Officer
Comp: $444.99k
Mr. Christopher Quesenberry
Chief Commercial Officer - Gimoti (TM)

Key Competitors

View All Competitors

EVOK Stock Analysis - Frequently Asked Questions

How have EVOK shares performed in 2024?: Evoke Pharma's stock was trading at $1.0503 at the beginning of the year. Since then, EVOK stock has decreased by 52.6% and is now trading at $0.4980.
View the best growth stocks for 2024 here.
Are investors shorting Evoke Pharma?: Evoke Pharma saw a decline in short interest in March. As of March 31st, there was short interest totaling 53,400 shares, a decline of 25.9% from the March 15th total of 72,100 shares. Based on an average daily volume of 62,100 shares, the short-interest ratio is currently 0.9 days. Currently, 0.8% of the shares of the company are sold short.
View Evoke Pharma's Short Interest.
When is Evoke Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our EVOK earnings forecast.
How were Evoke Pharma's earnings last quarter?: Evoke Pharma, Inc. (NASDAQ:EVOK) released its earnings results on Thursday, March, 14th. The specialty pharmaceutical company reported ($0.59) EPS for the quarter. The specialty pharmaceutical company earned $1.68 million during the quarter. Evoke Pharma had a negative net margin of 150.43% and a negative trailing twelve-month return on equity of 517.99%.

When did Evoke Pharma's stock split?: Evoke Pharma's stock reverse split before market open on Monday, May 23rd 2022. The 1-12 reverse split was announced on Monday, May 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What guidance has Evoke Pharma issued on next quarter's earnings?: Evoke Pharma issued an update on its FY 2024 earnings guidance on Thursday, March, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $14.0 million-$14.0 million, compared to the consensus revenue estimate of $14.0 million.
What other stocks do shareholders of Evoke Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Bed Bath & Beyond (BBBY).
How do I buy shares of Evoke Pharma?: Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVOK) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial